IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.765
EU - Europa 9.245
AS - Asia 8.636
SA - Sud America 2.754
AF - Africa 212
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 19
Totale 39.656
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.991
SG - Singapore 3.620
RU - Federazione Russa 3.172
BR - Brasile 2.259
IT - Italia 2.047
CN - Cina 2.040
VN - Vietnam 1.293
GB - Regno Unito 1.289
DE - Germania 738
CA - Canada 561
HK - Hong Kong 546
UA - Ucraina 438
IE - Irlanda 248
SE - Svezia 236
FR - Francia 219
AR - Argentina 197
IN - India 174
FI - Finlandia 173
MX - Messico 160
PL - Polonia 148
ID - Indonesia 136
BD - Bangladesh 134
TR - Turchia 132
DK - Danimarca 122
IL - Israele 114
NL - Olanda 108
ZA - Sudafrica 100
EC - Ecuador 93
ES - Italia 90
JP - Giappone 89
IQ - Iraq 76
AT - Austria 71
PK - Pakistan 63
CO - Colombia 56
AE - Emirati Arabi Uniti 42
LT - Lituania 39
PY - Paraguay 39
UZ - Uzbekistan 39
MA - Marocco 35
PE - Perù 27
CL - Cile 26
VE - Venezuela 24
EU - Europa 21
UY - Uruguay 19
KE - Kenya 17
TN - Tunisia 15
AZ - Azerbaigian 14
BE - Belgio 14
SA - Arabia Saudita 14
EG - Egitto 12
JO - Giordania 12
RO - Romania 12
BO - Bolivia 11
CH - Svizzera 11
DZ - Algeria 10
DO - Repubblica Dominicana 9
IR - Iran 9
KZ - Kazakistan 9
PH - Filippine 9
AU - Australia 8
HN - Honduras 8
MC - Monaco 8
NZ - Nuova Zelanda 8
AM - Armenia 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
AL - Albania 6
BY - Bielorussia 6
LB - Libano 6
NI - Nicaragua 6
OM - Oman 6
TH - Thailandia 6
JM - Giamaica 5
KW - Kuwait 5
NP - Nepal 5
PA - Panama 5
TW - Taiwan 5
BB - Barbados 4
BG - Bulgaria 4
CI - Costa d'Avorio 4
GE - Georgia 4
HU - Ungheria 4
KR - Corea 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
AO - Angola 3
BH - Bahrain 3
GR - Grecia 3
GT - Guatemala 3
GY - Guiana 3
IS - Islanda 3
LU - Lussemburgo 3
MD - Moldavia 3
MK - Macedonia 3
MY - Malesia 3
NG - Nigeria 3
PS - Palestinian Territory 3
RS - Serbia 3
SM - San Marino 3
BA - Bosnia-Erzegovina 2
Totale 39.612
Salva come PNG Salva come JPEG
Città #
Dallas 4.487
Singapore 1.941
Chicago 1.209
Ashburn 1.045
Beijing 1.001
Los Angeles 914
Moscow 584
Southend 540
Salt Lake City 526
Hong Kong 504
Chandler 443
Ho Chi Minh City 420
Fairfield 411
Buffalo 364
Woodbridge 330
San Mateo 329
Houston 327
Tampa 298
Wilmington 278
New York 276
Seattle 268
Ann Arbor 243
Dublin 240
Cambridge 236
Falls Church 232
São Paulo 232
Elk Grove Village 230
The Dalles 229
Hanoi 220
Hefei 218
Boardman 204
Jacksonville 183
Ottawa 182
Milan 180
Dearborn 162
Beauharnois 155
Portsmouth 153
Munich 145
Pisa 144
Stevenage 141
Santa Clara 134
Rome 128
Warsaw 128
Sterling 117
Dong Ket 115
Lawrence 106
Brooklyn 105
Lancaster 105
Tel Aviv 103
Montreal 99
London 94
Florence 88
Poplar 88
Tokyo 79
Rio de Janeiro 78
Miami 77
Frankfurt am Main 75
Phoenix 75
Denver 74
Istanbul 72
Stockholm 71
Johannesburg 69
Dulles 65
Atlanta 64
Mexico City 64
Nuremberg 62
Chennai 60
Orem 59
Belo Horizonte 53
Turku 51
Helsinki 50
San Diego 47
Lappeenranta 46
Detroit 45
Kansas City 45
Toronto 45
Amsterdam 42
Manchester 42
Boston 41
Brasília 41
Querétaro 41
Fremont 39
Washington 39
Haiphong 38
Porto Alegre 38
Curitiba 36
Redwood City 36
San Francisco 36
Tashkent 36
Council Bluffs 35
Da Nang 35
Bologna 34
Pittsburgh 34
Biên Hòa 33
Guangzhou 33
Ankara 32
Quito 32
Guayaquil 31
Lucca 31
Genoa 30
Totale 23.925
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.793
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.598
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.510
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 661
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 657
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 551
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 332
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 325
A simple echocardiographic score to rule out cardiac amyloidosis 306
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 298
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 293
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 280
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 277
Adrenergic activation in heart failure: blockade or rebalance? 276
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 275
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 268
A simple echocardiographic score to rule out cardiac amyloidosis 258
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 258
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 247
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 246
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 241
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 241
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 238
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 237
How to take arms against central apneas in heart failure 234
Sex-related differences in chronic heart failure 234
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 233
Cardiac light-chain deposition disease relapsing in the transplanted heart 232
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 232
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 227
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 226
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 223
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 222
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 222
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 221
Update sui biomarcatori nello scompenso cardiaco. 220
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 219
Screening the health status of people working in a university 218
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 218
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction 218
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 217
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 215
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 213
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 212
[Ten perspectives for research and innovation in cardiac amyloidosis] 211
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 206
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 206
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure 205
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 205
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 205
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 205
Atrial amyloidosis: mechanisms and clinical manifestations 204
Biomarkers for the diagnosis and management of heart failure 203
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 201
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 199
Prognostic value of plasma Renin activity in heart failure. 198
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 195
The search for efficient diagnostic and prognostic biomarkers of heart failure 194
Biomarkers for the diagnosis and management of heart failure: New frontiers 194
Eligibility for vericiguat in a real‐world, contemporary heart failure population 190
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 188
Modern diagnostic and therapeutical approach to cardiac AL amyloidosis and neuroendocrine model of heart failure: lessons from a clinical case. 187
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 187
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 185
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 184
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 180
Role of Imaging in Cardiomyopathies 179
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 179
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 179
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 179
Upright Cheyne-Stokes Respiration in Patients With Heart Failure 179
Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome 179
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 176
Cardiogenic shock and acute kidney injury: the rule rather than the exception 175
Renin profiling predicts neurohormonal response to sacubitril/valsartan 175
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 175
Management of complications of cardiac amyloidosis: 10 questions and answers 174
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 174
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 173
Valvular heart disease in patients with cardiac amyloidosis 170
Subclinical cardiac damage in cancer patients before chemotherapy 170
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 169
Disease features and management of cardiomyopathies in women 169
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week 169
Molecular autopsy of sudden cardiac death in the genomics era 169
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 168
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 167
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 166
Deep-learning-based cardiac amyloidosis classification from early acquired pet images 166
Classification of patients with cardiac amyloidosis using machine learning models on Italian electronic clinical health records 166
Epidemiological and clinical boundaries of heart failure with preserved ejection fraction 165
Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis 165
Heart, kidney and FGF23: Les liaisons dangereuses 164
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 164
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 164
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 162
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 162
N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure 160
RNA-targeting and gene editing therapies for transthyretin amyloidosis 159
Biomarkers for growth prediction of abdominal aortic aneurysm: A step forward(?) 159
Totale 26.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.216
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 203.216
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.512 0 0 0 0 0 286 198 136 187 151 243 311
2021/20221.911 161 295 80 196 74 67 201 333 141 195 36 132
2022/20231.334 109 110 62 140 164 175 36 120 251 30 82 55
2023/20241.331 76 36 239 101 73 120 102 65 51 75 55 338
2024/202513.502 112 132 487 200 420 489 1.183 2.120 812 2.024 3.134 2.389
2025/202617.110 1.474 4.063 3.958 3.848 2.785 982 0 0 0 0 0 0
Totale 39.931